Cheng-Yi Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cheng-Yi Chen has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Scattolin
Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States
10 shared publications - David Robinson Snead
Department of Chemical and Life Sciences Engineering, Virginia Commonwealth University, Richmond, Virginia 23284, United States
6 shared publications - Dinesh Jagannath Paymode
Mirati Therapeutics, Inc., 3545 Cray Ct, San Diego, California 92121, United States
4 shared publications Fengxian He
Porton (Shanghai) R&D Center , 1299 Ziyue Road, Zizhu Science Park, Minhang District, Shanghai 200241, China
3 shared publicationsGuangrong Tang
Porton (Shanghai) R&D Center , 1299 Ziyue Road, Zizhu Science Park, Minhang District, Shanghai 200241, China
3 shared publicationsRoger Faessler
Janssen R&D, Pharmaceutical Development and Manufacturing Sciences, Small Molecule API Switzerland, Cilag AG , Hochstrasse 201, 8205 Schaffhausen, Switzerland
3 shared publications
Latest Publications
- Open Access
- 10 April 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (8) , 3128-3142
Adagrasib’s Second-Generation Synthesis: Transitioning from Route Scouting to Optimization
- 10 April 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (8) , 3128-3142
Open AccessAdagrasib’s Second-Generation Synthesis: Transitioning from Route Scouting to Optimization
- 26 January 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (2) , 609-618
Process Development and Manufacture of the Core Starting Material of Adagrasib (MRTX849)
- 26 January 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (2) , 609-618
Process Development and Manufacture of the Core Starting Material of Adagrasib (MRTX849)
- Open Access
- 20 December 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Process Development and Manufacture of the Core Starting Material of Adagrasib (MRTX849)
The beta-ketoester 1 is one of the critical starting materials used in the second-generation synthesis of adagrasib. Disclosed within is a new, streamlined, operationally simple and more environmentally friendly three-step telescoped protocol which was demonstrated on a >100 kg batch with an overall yield of 70%. Identification of the shortcomings and the quality issues of the initial route are discussed. The process development work overcoming these challenges and leading to the new route of synthesis is described.
- 20 December 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessProcess Development and Manufacture of the Core Starting Material of Adagrasib (MRTX849)
The beta-ketoester 1 is one of the critical starting materials used in the second-generation synthesis of adagrasib. Disclosed within is a new, streamlined, operationally simple and more environmentally friendly three-step telescoped protocol which was demonstrated on a >100 kg batch with an overall yield of 70%. Identification of the shortcomings and the quality issues of the initial route are discussed. The process development work overcoming these challenges and leading to the new route of synthesis is described.
- 30 November 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (12) , 2393-2399
Stereochemical Editing via Coupled Epimerization and Optical Resolution to Sustainably Manufacture a Key Adagrasib Building Block
- 30 November 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (12) , 2393-2399
Stereochemical Editing via Coupled Epimerization and Optical Resolution to Sustainably Manufacture a Key Adagrasib Building Block
- Open Access
- 22 May 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (6) , 1061-1068
Process Development and Scale-Up of the SOS1 Inhibitor MRTX0902
- 22 May 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (6) , 1061-1068
Open AccessProcess Development and Scale-Up of the SOS1 Inhibitor MRTX0902
- Open Access
- 10 May 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (5) , 954-971
Scalable Atroposelective Synthesis of MRTX1719: An Inhibitor of the PRMT5/MTA Complex
- 10 May 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (5) , 954-971
Open AccessScalable Atroposelective Synthesis of MRTX1719: An Inhibitor of the PRMT5/MTA Complex
- 17 February 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (3) , 530-538
Development of Adagrasib’s Commercial Manufacturing Route
- 17 February 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (3) , 530-538
Development of Adagrasib’s Commercial Manufacturing Route
- Open Access
- 1 February 2023
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 25 (6) , 944-949
Synthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug for the Treatment of Cancer
A concise, transition-metal and protection-free synthesis of adagrasib (MRTX849), a novel KRASG12C inhibitor drug recently approved by the FDA, is reported. Introduction of two chiral building blocks to the tetrahydropyridopyrimidine core was accomplished via two sequential SNAr reactions. Extensive reaction optimization led to a robust, transition-metal-free oxidation of the sulfide intermediate. A judicious choice of the leaving group with favorable steric and electronic characteristics at the 4-OH position of the tetrahydropyridopyrimidine core enabled a facile SNAr displacement to introduce the chiral piperazine. This new, five-step, chromatography-free synthesis of adagrasib from readily available starting materials obviated the palladium catalysis and protecting group manipulations in the current commercial route and significantly improved the efficiency of the process in 45% overall yield.
- 1 February 2023
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 25 (6) , 944-949
Open AccessSynthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug for the Treatment of Cancer
A concise, transition-metal and protection-free synthesis of adagrasib (MRTX849), a novel KRASG12C inhibitor drug recently approved by the FDA, is reported. Introduction of two chiral building blocks to the tetrahydropyridopyrimidine core was accomplished via two sequential SNAr reactions. Extensive reaction optimization led to a robust, transition-metal-free oxidation of the sulfide intermediate. A judicious choice of the leaving group with favorable steric and electronic characteristics at the 4-OH position of the tetrahydropyridopyrimidine core enabled a facile SNAr displacement to introduce the chiral piperazine. This new, five-step, chromatography-free synthesis of adagrasib from readily available starting materials obviated the palladium catalysis and protecting group manipulations in the current commercial route and significantly improved the efficiency of the process in 45% overall yield.
- Open Access
- 5 January 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Process Development and Scale-Up of the SOS1 Inhibitor MRTX0902
MRTX0902, a novel SOS1 inhibitor, is currently being evaluated in phase I trials for the treatment of cancer. The complexity of the molecule containing a pyrido[3,4-d]pyridazine core and a chiral amine moiety makes it a challenging target to prepare on multi-kilogram scale to support clinical development studies. An efficient and scalable synthesis to the key intermediate, 4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1(2H)-one and a much improved end-game to MRTX0902 was developed.
- 5 January 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessProcess Development and Scale-Up of the SOS1 Inhibitor MRTX0902
MRTX0902, a novel SOS1 inhibitor, is currently being evaluated in phase I trials for the treatment of cancer. The complexity of the molecule containing a pyrido[3,4-d]pyridazine core and a chiral amine moiety makes it a challenging target to prepare on multi-kilogram scale to support clinical development studies. An efficient and scalable synthesis to the key intermediate, 4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1(2H)-one and a much improved end-game to MRTX0902 was developed.
- Open Access
- 12 December 2022
- Published by American Chemical Society (ACS) in ChemRxiv
Development of Adagrasib’s Commercial Manufacturing Route
A commercial route to MRTX849 (adagrasib) was developed to support clinical and commercial needs. Yield was improved to 32% over six chemical steps. A doubly regioselective SNAr reduced consumption of an expensive chiral intermediate, reaction optimization led to parts per million palladium catalysis, and a new method to deprotect Cbz-groups were developed to mitigate risk associated with benzyl iodide.
- 12 December 2022
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of Adagrasib’s Commercial Manufacturing Route
A commercial route to MRTX849 (adagrasib) was developed to support clinical and commercial needs. Yield was improved to 32% over six chemical steps. A doubly regioselective SNAr reduced consumption of an expensive chiral intermediate, reaction optimization led to parts per million palladium catalysis, and a new method to deprotect Cbz-groups were developed to mitigate risk associated with benzyl iodide.